Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

doi:10.1016/j.ccell.2017.11.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Cancer cell - 8 Jan 2018

Kleppe Maria, Koche Richard, Zou Lihua, van Galen Peter, Hill Corinne E, Dong Lauren, De Groote Sofie, Papalexi Efthymia, Hanasoge Somasundara Amritha V, Cordner Keith, Keller Matthew, Farnoud Noushin, Medina Juan, McGovern Erin, Reyes Jaime, Roberts Justin, Witkin Matthew, Rapaport Franck, Teruya-Feldstein Julie, Qi Jun, Rampal Raajit, Bernstein Bradley E, Bradner James E, Levine Ross L

Abstract excerpt

Genetic and functional studies underscore the central role of JAK/STAT signaling in myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate transformation in MPNs are not fully delineated, and clinically utilized JAK inhibitors have limited ability to reduce disease burden or reverse myelofibrosis. Here we show that MPN progenitor cells are characterized by marked alterations in gene regulation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inflammation

Share to Janus Kinase 2

Share to Mice, Transgenic

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to NF-kappa B

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 29249691
DOI: 10.1016/j.ccell.2017.11.009
PMCID: PMC5760343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.PMID 29249691Read ↗

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Semantic proximity Read ↗

In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasmsSemantic proximity Read ↗

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.Semantic proximity Read ↗

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted TherapiesSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cellsSemantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.